Pfizer and biontech announce updated clinical data for omicron ba.4/ba.5-adapted bivalent booster demonstrating substantially higher immune response in adults compared to the original covid-19 vaccine

New york and mainz, germany, november 4, 2022 — pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced updated data from a phase 2/3 clinical trial demonstrating a robust neutralizing immune response one-month after a 30-Μg booster dose of the companies' omicron ba.4/ba.5-adapted bivalent covid-19 vaccine (pfizer-biontech covid-19 vaccine, bivalent (original and omicron ba.4/ba.5)). immune responses against ba.4/ba.5 sublineages were substantially higher for those who received the bivalent vaccine compared to the companies' original covid-19 vaccine, with a similar safety and tolerability profile between both vaccines. these results reinforce the previously reported early clinical data measured 7 days after a booster dose of the bivalent vaccine, as well as the pre-clinical data , and suggest that a 30-Μg booster dose of the omicron ba.4/ba.5-adapted bivalent vaccine may induce a higher level of protection against the omicron ba.4 and ba.5 sublineages than the original vaccine.
BNTX Ratings Summary
BNTX Quant Ranking